(MedPage Today) — Based on results from the DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd; Enhertu) became the preferred, guideline-supported, second-line therapy for HER2-positive metastatic breast cancer, regardless of hormone receptor…
Source: MedPage Today — Headlines
